Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.71 |
| ▸ | OPRL1 | P41146 | 16/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20229794 | 0.90 | OPRM1 (0.73) | OPRM1OPRL1OPRK1OPRD1OGFRL1 | |
| SCHEMBL20230048 | 0.87 | OPRM1 (0.60) | OPRM1OPRL1OPRK1OPRD1OGFRL1 | |
| SCHEMBL20230120 | 0.87 | OPRM1 (0.69) | OPRM1OPRL1OPRK1OPRD1OGFRL1 | |
| SCHEMBL20213174 | 0.87 | OPRM1 (0.54) | OPRM1OPRL1OPRK1 | |
| SCHEMBL20229838 | 0.86 | OPRM1 (0.76) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20212790 | 0.86 | OPRM1 (0.76) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL20212793 | 0.86 | OPRM1 (0.56) | OPRM1OPRL1OPRK1 | |
| SCHEMBL20230157 | 0.86 | OPRM1 (0.78) | OPRM1OPRL1OPRK1OPRD1OGFRL1 | |
| SCHEMBL23034899 | 0.86 | OPRM1 (0.53) | OPRM1OPRL1OPRK1 | |
| SCHEMBL20230118 | 0.86 | OPRM1 (0.74) | OPRM1OPRL1OPRK1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155314-A1 | PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS | ASTRAEA THERAPEUTICS, LLC | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155314-A1 | PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.